| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/23/2006 | US20060040262 Novel compositions and methods in cancer |
| 02/23/2006 | US20060039989 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039962 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
| 02/23/2006 | US20060039953 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/23/2006 | US20060039947 Biologically active implants |
| 02/23/2006 | US20060039930 Methods for enhancing wound healing |
| 02/23/2006 | US20060039918 Stress proteins and peptides and methods of use thereof |
| 02/23/2006 | US20060039917 Method for treating phantom pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039916 Method for treating complex regional pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039915 P-cadherin as a target for anti-cancer therapy |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | US20060039883 Biologically active compounds for the modification of bodily odours |
| 02/23/2006 | US20060037910 Comprise liquid or dry acid concentrate unit stored in first vessel, and liquid or dry citrate-containing bicarbonate concentrate unit stored in second vessel; contents of first and second vessels are emptied into dialysate preparation tank and mixed with water to form batch of dialysate |
| 02/23/2006 | DE102004038886A1 Pharmaceutical formulation useful for treating inflammatory and obstructive respiratory diseases comprises at least one anticholinergic compound, at least one corticosteroid and at least one betamimetic |
| 02/23/2006 | DE102004037505A1 Präbiotische Intimpflege Prebiotic intimate care |
| 02/23/2006 | DE102004013294A1 Use of tropisetron and/or 5-hydroxy tryptophan-3-receptor-antagonist to reduce apoplectic condition in an infarct area by blocking serotonin-3-receptor, down-regulate inflammation process and strengthen the serotonin receptor expression |
| 02/23/2006 | CA2781626A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | CA2619779A1 Use of a pde5 inhibitor for treating and preventing hypopigmentary disorders |
| 02/23/2006 | CA2577213A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 02/23/2006 | CA2576156A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | CA2575563A1 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 02/23/2006 | CA2575155A1 Use of vitamin ds to treat kidney disease |
| 02/22/2006 | EP1627644A1 PREPARTAION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1a PRODUC TION INHIBITOR |
| 02/22/2006 | EP1627643A2 Vascular endothelial cell growth factor antagonists |
| 02/22/2006 | EP1627639A2 Use of COX-2 inhibitors for the treatment of affective disorders |
| 02/22/2006 | EP1627638A1 Fortifier |
| 02/22/2006 | EP1627039A2 Ingestible gastrointestinal device |
| 02/22/2006 | EP1626989A2 Method of treating corneal transplant rejection by using vegf antagonists |
| 02/22/2006 | EP1626738A2 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 02/22/2006 | EP1626731A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 02/22/2006 | EP1626724A2 Method and kit for regulation of microvascular tone |
| 02/22/2006 | EP1626721A2 Carbostyril derivatives and mood stabilizers for treating mood disorders |
| 02/22/2006 | EP1626719A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 02/22/2006 | EP1626714A2 Diaryl ureas for diseases mediated by pdgfr |
| 02/22/2006 | EP1626706A2 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals |
| 02/22/2006 | EP1626693A2 Ginkgo biloba extract as a treatment for therapeutic- induced neurotoxicity |
| 02/22/2006 | EP1626648A2 Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer s disease |
| 02/22/2006 | EP1406622B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/22/2006 | EP1385856B1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/22/2006 | EP1251857B1 Pharmaceutical parenteral composition containing a bisphosphonate |
| 02/22/2006 | EP1225881B1 The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction |
| 02/22/2006 | EP1212464B1 Diagnostics and therapeutics for osteoporosis |
| 02/22/2006 | EP1121431B1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 02/22/2006 | EP1093370B1 Pharmaceutical composition for the treatment of diabetes |
| 02/22/2006 | EP1047788B1 Method of determining metastatic potential employing the asp1 gene |
| 02/22/2006 | EP1003844B1 Kinase activating dependent cyclin protein kinases, and their uses |
| 02/22/2006 | EP0957929B1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/22/2006 | EP0814837B2 Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 02/22/2006 | CN1739030A Diagnosis and prevention of cancer cell invasion |
| 02/22/2006 | CN1738665A Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases |
| 02/22/2006 | CN1738636A Use of enzyme inhibitors with aminopeptidase N and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases wit |
| 02/22/2006 | CN1738635A Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
| 02/22/2006 | CN1738634A Extract of stephaniae sinica diels and methods of using the same |
| 02/22/2006 | CN1738627A Method for inhibition of necrosis induced by neurotrophin |
| 02/22/2006 | CN1738618A Pharmaceutical compositions and their uses |
| 02/22/2006 | CN1738610A Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| 02/22/2006 | CN1738604A Powder pharmaceutical compositions |
| 02/22/2006 | CN1738599A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/22/2006 | CN1738595A Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| 02/22/2006 | CN1736487A Bioimplant formulation |
| 02/22/2006 | CN1736486A Anticancer implantation agent |
| 02/22/2006 | CN1736485A Use of vanillin receptor agonist in preparation of product for resisting Alzheimer disease |
| 02/22/2006 | CN1736484A Method for preparing nanometer particle of galactose sodium alginate-polylysine |
| 02/22/2006 | CN1736483A Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| 02/22/2006 | CN1736376A Modulation of peroxisome proliferator-activated receptors |
| 02/22/2006 | CN1243021C Interleukin-18 binding proteins, their preparation and use |
| 02/22/2006 | CN1242813C Combination therapy for osteoporosis |
| 02/22/2006 | CN1242809C Applications of T-BAM (CD40L) technology in preparation of medicine to treat diseases involving smooth muscle cell |
| 02/22/2006 | CN1242750C Biodegradable and biocompatible polymeric microsphores encapsulating salmonella enteritidis bacteria |
| 02/22/2006 | CN1242744C Nasal cavity preparation for treating long-term allergic reaction coryza |
| 02/22/2006 | CN1242741C Preparation and diabetic use of gibberellins |
| 02/21/2006 | US7001991 transferrin-doxorubicin linked with glutaraldehyde; low-toxicity, side-effect reduction |
| 02/21/2006 | US7001989 Conjugates comprising two active agents |
| 02/21/2006 | US7001910 substituted pyrimidinyl-amino-ethoxy benzyl-thiazolidine-diones; hypoglycemic agents |
| 02/21/2006 | US7001907 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 02/21/2006 | US7001886 Hot melt method for preparing diphenhydramine tannate |
| 02/21/2006 | US7001775 associated with autoimmune thyroid disease; colorimetric immunoassay; contacting fluids with immobilized antibodies, labeling and monitoring; simple, rapid |
| 02/21/2006 | US7001756 and hypercholesterolemia, atherosclerosis and coronary heart disease; dosage forms; use with Auricularia polytricha (wood ear), an edible fungi |
| 02/21/2006 | US7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 02/21/2006 | US7001718 Prevent complexing of Dna and ligand; viricides; drug mixture with carrier |
| 02/21/2006 | US7001620 Kavalactone product |
| 02/21/2006 | US7001612 For restoration of electrolyte balance due to sweating in the absence of strenuous physical exertion; beverages |
| 02/21/2006 | US7001602 Administering a neurotoxin ; therapy for enlargement of prostate gland |
| 02/21/2006 | US7001601 keyhole limpet hemocyanin (KLH) and adjuvant (QS-21; saponin derivative); immunogens; for treatment of melanomas |
| 02/21/2006 | US7001597 Methods for altering fertility |
| 02/21/2006 | US7001589 comprises liquid core (containing hydrocarbon) and water soluble polymethylacrylamides as skins/envelopes; microencapsulation; kits |
| 02/21/2006 | US7001430 Matrix composition for human grafts/implants |
| 02/21/2006 | CA2356306C Sulfated phosphatidylinositols, their preparation and use |
| 02/16/2006 | WO2006017563A2 Compositions and methods for reversing age-related changes in extracellular matrix proteins |
| 02/16/2006 | WO2006017505A2 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases |
| 02/16/2006 | WO2006017369A2 Use of a farnesyl transferase inhibitor in the treatment of viral infections |
| 02/16/2006 | WO2006017188A2 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 02/16/2006 | WO2006016695A1 Preventive and/or remedy for hyperkalemia containing ep4 agonist |
| 02/16/2006 | WO2006016657A1 Drug for treating or preventing hcv infection |
| 02/16/2006 | WO2006016574A1 ANTINEOPLASTIC AGENT APPLYING RNAi |
| 02/16/2006 | WO2006016530A1 Transnasal composition having immediate action and high absorbability |
| 02/16/2006 | WO2006016468A1 Method of producing liposome-containing preparation |
| 02/16/2006 | WO2006016363A2 Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions |
| 02/16/2006 | WO2006016353A2 Elastase inhibitor in leukemia |